Neonatal Head Circumference in Newborns With Neonatal Abstinence Syndrome.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
01 2019
Historique:
accepted: 16 10 2018
pubmed: 12 12 2018
medline: 16 10 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

To compare head circumference (HC) in neonates treated for neonatal abstinence syndrome (NAS) with control neonates without antenatal opioid exposure. Our prospective cohort study ran from April 1, 2014, through December 31, 2016. Newborns treated for NAS delivered from well-dated pregnancies ≥34 weeks' gestation were compared with newborns who were nonopioid exposed and matched for race, parity, mode of delivery, and gestational age. All mothers underwent serial antenatal urine drug testing. A minimum of 754 study participants were needed (377 in each group) to demonstrate an increase in the proportion of newborns with HCs less than or equal to the 10th percentile from 10% in controls to a minimum of 20% in NAS newborns with 90% power. A total of 858 neonates were enrolled (429 NAS cases and 429 controls). Mean HC for cases was 33.04 cm (±1.9 cm) compared with 33.99 cm (±2.0 cm) for controls ( Chronic opioid use during pregnancy sufficient to cause NAS was associated with smaller HCs at birth. Most mothers were on opioid agonist medication-assisted treatment, which is currently the recommended treatment option during pregnancy.

Identifiants

pubmed: 30530638
pii: peds.2018-0541
doi: 10.1542/peds.2018-0541
pii:
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Auteurs

Craig V Towers (CV)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee ctowers@utmck.edu.

Branson W Hyatt (BW)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.

Kevin C Visconti (KC)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.

Lindsey Chernicky (L)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.

Katie Chattin (K)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.

Kimberly B Fortner (KB)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH